In addition, a series of in vitro and in vivo experiments demonstrated that miR-939 diminishes GC cell chemoresistance and metastatic ability by targeting SLC34A2 expression, with consequent inhibition of the Raf-MEK-ERK signaling pathway. Here, SLC34A2 is linked to gastric cancer.